Skip to content

Clindamycin pharmacokinetics during obstetric or fetal surgery

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-503653-35-00
Acronym
S-67465
Enrollment
0
Registered
2023-08-30
Start date
2023-12-11
Completion date
2024-12-17
Last updated
2023-09-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prophylaxis (antibiotics) during maternal or fetal surgery

Brief summary

A population pharmacokinetic analysis approach will be performed, comparing the data on PK already reported in adults or other pregnant women and the newly collected data during pregnancy. The quality of fit of the pharmacokinetic model to the data will be sought by NONMEM's objective function and by visual examination of plots of observed vs predicted concentrations. Clindamycin concentrations in maternal plasma and amniotic fluid will be measured at the different sample collection timepoints.

Detailed description

Pharmacokinetic analysis, including the covariates of interest or relevant clinical characteristics i.e., body weight, length, age, body surface area (BSA), gestational age, type of delivery, intercurrent co-morbidity (e.g., renal and hepatic dysfunction, hypothermia, hypothyroidism), other parenteral or other co-medications.

Interventions

DRUGDalacin C 600 mg solution injectable

Sponsors

UZ Leuven
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Design outcomes

Secondary

MeasureTime frame
Pharmacokinetic analysis, including the covariates of interest or relevant clinical characteristics i.e., body weight, length, age, body surface area (BSA), gestational age, type of delivery, intercurrent co-morbidity (e.g., renal and hepatic dysfunction, hypothermia, hypothyroidism), other parenteral or other co-medications.

Primary

MeasureTime frame
A population pharmacokinetic analysis approach will be performed, comparing the data on PK already reported in adults or other pregnant women and the newly collected data during pregnancy. The quality of fit of the pharmacokinetic model to the data will be sought by NONMEM's objective function and by visual examination of plots of observed vs predicted concentrations. Clindamycin concentrations in maternal plasma and amniotic fluid will be measured at the different sample collection timepoints.

Countries

Belgium

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026